Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-ope...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/full |
| _version_ | 1827943130707525632 |
|---|---|
| author | Julien Ancel Julien Ancel Valérian Dormoy Béatrice Nawrocki Raby Véronique Dalstein Véronique Dalstein Anne Durlach Anne Durlach Maxime Dewolf Christine Gilles Myriam Polette Myriam Polette Gaëtan Deslée Gaëtan Deslée |
| author_facet | Julien Ancel Julien Ancel Valérian Dormoy Béatrice Nawrocki Raby Véronique Dalstein Véronique Dalstein Anne Durlach Anne Durlach Maxime Dewolf Christine Gilles Myriam Polette Myriam Polette Gaëtan Deslée Gaëtan Deslée |
| author_sort | Julien Ancel |
| collection | DOAJ |
| description | Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological–driven decision. |
| first_indexed | 2024-03-13T10:09:49Z |
| format | Article |
| id | doaj.art-bc95270bed864c468dac1936841ff690 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T10:09:49Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-bc95270bed864c468dac1936841ff6902023-05-22T04:43:33ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-05-011410.3389/fimmu.2023.11716491171649Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitorsJulien Ancel0Julien Ancel1Valérian Dormoy2Béatrice Nawrocki Raby3Véronique Dalstein4Véronique Dalstein5Anne Durlach6Anne Durlach7Maxime Dewolf8Christine Gilles9Myriam Polette10Myriam Polette11Gaëtan Deslée12Gaëtan Deslée13Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceDepartment of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceDepartment of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceDepartment of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceDepartment of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceLaboratory of Tumor and Development Biology, GIGA-Cancer, University of Liège, Liège, BelgiumInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceDepartment of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceInserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, FranceDepartment of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, FranceLung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological–driven decision.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/fullliquid biopsysoluble biomarkersimmunotherapynon-small cell lung cancer (NSCLC)neutrophil lymphocyte ratio (NLR)circulating tumor (ctDNA) |
| spellingShingle | Julien Ancel Julien Ancel Valérian Dormoy Béatrice Nawrocki Raby Véronique Dalstein Véronique Dalstein Anne Durlach Anne Durlach Maxime Dewolf Christine Gilles Myriam Polette Myriam Polette Gaëtan Deslée Gaëtan Deslée Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors Frontiers in Immunology liquid biopsy soluble biomarkers immunotherapy non-small cell lung cancer (NSCLC) neutrophil lymphocyte ratio (NLR) circulating tumor (ctDNA) |
| title | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors |
| title_full | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors |
| title_fullStr | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors |
| title_full_unstemmed | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors |
| title_short | Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors |
| title_sort | soluble biomarkers to predict clinical outcomes in non small cell lung cancer treated by immune checkpoints inhibitors |
| topic | liquid biopsy soluble biomarkers immunotherapy non-small cell lung cancer (NSCLC) neutrophil lymphocyte ratio (NLR) circulating tumor (ctDNA) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/full |
| work_keys_str_mv | AT julienancel solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT julienancel solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT valeriandormoy solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT beatricenawrockiraby solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT veroniquedalstein solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT veroniquedalstein solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT annedurlach solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT annedurlach solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT maximedewolf solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT christinegilles solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT myriampolette solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT myriampolette solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT gaetandeslee solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors AT gaetandeslee solublebiomarkerstopredictclinicaloutcomesinnonsmallcelllungcancertreatedbyimmunecheckpointsinhibitors |